Medtronic bone graft qualifies for NTAP status

Advertisement

Medtronic’s Infuse Bone Graft for TLIF will qualify for a Medicare New Technology Add-on Payment effective Oct. 1.

CMS granted the add-on payment for Infuse, according to a Sept. 2 news release from the company.

NTAP status is a Medicare fee for service inpatient reimbursement mechanism for qualifying technologies. It provides additional reimbursement for certain cases when the cost of a new technology exceeds the standard payment amount.

Infuse bone graft received FDA premarket approval for TLIF earlier in 2026 after receiving breakthrough device designation and a prioritized review timeline, the release said.

Advertisement

Next Up in Spinal Tech

Advertisement